SOURCE: SomaLogic


February 04, 2015 11:00 ET

SomaLogic Announces Agreement to Place SOMAscan™ Proteomics Assay at Manitoba Centre for Proteomics and Systems Biology

BOULDER, CO--(Marketwired - February 04, 2015) - SomaLogic, Inc., announced today that the University of Manitoba's Centre for Proteomics and Systems Biology (MCPSB) is the first SOMAscan™ assay "Early Access" site outside of the United States. It is expected that the assay will be installed and fully functional at the Centre by the middle of 2015, under the leadership of Director John A. Wilkins, Ph.D.

"MCPSB is dedicated to the promotion and practice of Systems Biology and Proteomics in Manitoba, both in academia and industry," said Dr. Wilkins. "The addition of the SOMAscan assay gives us a powerful new platform to complement our existing proteomic capabilities. We see unique potential for SOMAscan-based applications in basic and applied biomedical research."

Compared to other current proteomic technologies, SomaLogic's offerings provide researchers with unprecedented power for protein biomarker discovery, diagnostics development, and pharmaceutical discovery and development. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1129 different SOMAmer reagents, can efficiently, accurately, and rapidly measures proteins across a wide range of concentrations in small volumes of multiple biological sample types.

"We are delighted to work with Dr. Wilkins and his colleagues at the University of Manitoba to expand their access to the SOMAscan platform, and we anticipate that many new discoveries and insights into human biology and disease will come out of this collaboration," said Byron Hewett, Chief Executive Officer of SomaLogic.

SomaLogic is continuing to expand access to its SOMAscan assay through its placement in leading academic research centers. Current sites, in addition to MCPSB, include Massachusetts General Hospital, the University of Pennsylvania, the US National Institutes of Health, and the University of Colorado Denver, with several more expected to be announced in the coming months.

About SomaLogic

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colo. The company's mission is to use its proprietary modified aptamer-based proteomic technologies to develop a wide range of enhanced protein-analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of health care by offering timely and accurate diagnostic information to physicians and their patients. Further information about SomaLogic can be found at

Contact Information